

Yi-Hsiang Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/115554/publications.pdf>

Version: 2024-02-01

354
papers

13,122
citations

47409

49
h-index

39744

98
g-index

363
all docs

363
docs citations

363
times ranked

13583
citing authors

#	ARTICLE	IF	CITATIONS
1	Cryptogenic hepatocellular carcinoma: characteristics, outcome, and prognostic role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 61-69.	0.6	4
2	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1151-1162.e6.	2.4	14
3	Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 311-322.	1.1	15
4	Significance of high serum IgG4 in complete or non-full-fledged IgG4-related disease—a retrospective investigation of 845 patients and its clinical relevance. <i>Clinical Rheumatology</i> , 2022, 41, 115-122.	1.0	1
5	Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 30-41.	0.6	7
6	A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 19-27.	0.7	2
7	Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: With emphasis on the impact of chronic hepatitis B infection. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 286-294.	0.6	4
8	Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 152-159.	0.6	3
9	Alteration of gut microbial composition associated with the therapeutic efficacy of fecal microbiota transplantation in <i>Clostridium difficile</i> infection. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1636-1646.	0.8	4
10	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. <i>BMC Cancer</i> , 2022, 22, 55.	1.1	14
11	A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 649.	1.7	17
12	Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 218.	1.7	13
13	Contemporary real-world evidence in unresectable HCC (uHCC) patients treated with regorafenib in Taiwan: Interim results from the observational REFINE study. <i>Journal of Clinical Oncology</i> , 2022, 40, 402-402.	0.8	0
14	Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs). <i>Journal of Clinical Oncology</i> , 2022, 40, 399-399.	0.8	1
15	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	0.8	2
16	Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade. <i>International Journal of Clinical Oncology</i> , 2022, 27, 739-748.	1.0	5
17	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. <i>Viruses</i> , 2022, 14, 333.	1.5	2
18	AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review. <i>Liver Cancer</i> , 2022, 11, 94-112.	4.2	10

#	ARTICLE	IF	CITATIONS
19	Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2631-2643.	2.0	23
20	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	3.6	114
21	Differential prognoses among male and female patients with hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 554-565.	0.6	11
22	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	1.7	44
23	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 485-500.	1.8	13
24	Determinants of Survival and Post-Progression Outcomes by Sorafenib/Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2014.	1.7	5
25	Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 2085-2092.	0.8	5
26	Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. <i>Investigational New Drugs</i> , 2022, 40, 789-797.	1.2	14
27	Comparison of prognoses between cirrhotic and noncirrhotic patients with hepatocellular carcinoma and esophageal varices undergoing surgical resection. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 679-686.	0.6	5
28	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	2.0	7
29	Surgical resection could provide better outcomes for patients with hepatocellular carcinoma and tumor rupture. <i>Scientific Reports</i> , 2022, 12, 8343.	1.6	5
30	Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210994.	1.4	1
31	Outcomes of patients with malignant duodenal obstruction after receiving self-expandable metallic stents: A single center experience. <i>PLoS ONE</i> , 2022, 17, e0268920.	1.1	4
32	Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan. <i>Liver Cancer</i> , 2022, 11, 426-439.	4.2	11
33	Role of organ-specific response to immune checkpoint inhibitor in survival for advanced hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, e16172-e16172.	0.8	0
34	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. <i>Journal of Clinical Oncology</i> , 2022, 40, e004205.		26
35	Relationship between systemic inflammatory response markers and immune treatment related toxicity (IrAEs) in hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2022, 40, e16204-e16204.	0.8	1
36	Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?. <i>World Journal of Hepatology</i> , 2022, 14, 1074-1086.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. , 2022, 10, e004779.		47
38	Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 385-395.	1.5	14
39	Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1730-1738.	1.1	10
40	Prediction of survival according to kinetic changes of cytokines and hepatitis status following radioembolization with yttrium-90 microspheres. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1127-1136.	0.8	5
41	Active Vitamin D ₃ Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000937.	1.5	20
42	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1051-1060.	0.8	72
43	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	2.6	31
44	Intestinal SIRT1 Deficiency-Related Intestinal Inflammation and Dysbiosis Aggravate TNF α -Mediated Renal Dysfunction in Cirrhotic Ascitic Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1233.	1.8	6
45	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110109.	1.4	15
46	Loss of Tid1/DNAJA3 Co-Chaperone Promotes Progression and Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Novel Model to Stratify Risk of Recurrence. <i>Cancers</i> , 2021, 13, 138.	1.7	5
47	The role of albumin-bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 136-143.	0.6	8
48	Differences in intestinal microbiota profiling after upper and lower gastrointestinal surgery. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 354-360.	0.6	1
49	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	1.9	29
50	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2247-2254.	1.4	3
51	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
52	Prophylactic clipping after endoscopic mucosal resection of large nonpedunculated colorectal lesions: A meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1778-1787.	1.4	9
53	Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 465-471.	0.6	5
54	Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 472-477.	0.6	2

#	ARTICLE	IF	CITATIONS
55	ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 722-734.	0.6	1
56	Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16138-e16138.	0.8	3
57	Association of gut microbiota and metabolites with tumor response to immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16165-e16165.	0.8	2
58	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2884-2892.	1.4	10
59	Fecal microbiota profile in patients with inflammatory bowel disease in Taiwan. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 580-587.	0.6	6
60	Sulfamethoxazole-trimethoprim-induced liver injury and genetic polymorphisms of NAT2 and CYP2C9 in Taiwan. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 200-206.	0.7	1
61	Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury. <i>Cells</i> , 2021, 10, 1562.	1.8	12
62	Easy albumin-bilirubin score as a new prognostic predictor in hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 1129-1138.	1.8	17
63	Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1393-1399.	0.5	13
64	Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3196-3203.	1.4	21
65	Roles and mechanisms of circulating CEACAM1 in the cirrhosis-related intestinal hyperpermeability: in vitro approach. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 851-859.	0.6	1
66	Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. <i>Liver Cancer</i> , 2021, 10, 629-640.	4.2	27
67	Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. <i>Liver International</i> , 2021, 41, 2671-2680.	1.9	9
68	Abstract 485: Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study. , 2021, , .		2
69	Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort. <i>Hepatology</i> , 2021, 74, 1994-2006.	3.6	13
70	Glycyrrhizin Attenuates Portal Hypertension and Collateral Shunting via Inhibition of Extrahepatic Angiogenesis in Cirrhotic Rats. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7662.	1.8	6
71	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 809-822.	1.8	17
72	Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. <i>Cancers</i> , 2021, 13, 4325.	1.7	8

#	ARTICLE	IF	CITATIONS
73	High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9116.	1.8	9
74	Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury. <i>Hepatology International</i> , 2021, 15, 1456-1465.	1.9	10
75	Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1563-1571.	0.8	14
76	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021, 15, 1109-1121.	1.9	4
77	The clinical significance of esophagogastric varices in patients with advanced pancreatic cancer. <i>Journal of the Chinese Medical Association</i> , 2021, Publish Ahead of Print, 917-922.	0.6	1
78	Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 993-1000.	0.6	8
79	Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2021, 21, 984.	1.3	1
80	REPLY:. <i>Hepatology</i> , 2021, 74, 2925-2926.	3.6	0
81	Evolutionary Learning-Derived Clinical-Radiomic Models for Predicting Early Recurrence of Hepatocellular Carcinoma after Resection. <i>Liver Cancer</i> , 2021, 10, 572-582.	4.2	21
82	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	1.3	42
83	Deletion of intestinal SIRT1 exacerbated muscle wasting in cirrhotic mice by decreasing the intestinal concentration of short-chain fatty acids and inflammation. <i>Journal of Pharmacological Sciences</i> , 2021, 147, 376-385.	1.1	8
84	(Pro)renin Receptor Knockdown Attenuates Liver Fibrosis Through Inactivation of ERK/TGF- β 1/SMAD3 Pathway. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 813-838.	2.3	13
85	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	4.2	33
86	Matrix metalloproteinase-9 inhibition or deletion attenuates portal hypertension in rodents. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10073-10087.	1.6	5
87	Outcomes of Patients with Malignant Esophagogastric Junction Obstruction Receiving Metallic Stents. <i>Journal of the Chinese Medical Association</i> , 2021, Publish Ahead of Print, .	0.6	1
88	Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients. <i>PLoS ONE</i> , 2021, 16, e0258589.	1.1	5
89	Genetic variations of three important antioxidative enzymes SOD2, CAT, and GPX1 in nonalcoholic steatohepatitis. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 14-18.	0.6	8
90	Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg. <i>American Journal of Cancer Research</i> , 2021, 11, 3711-3725.	1.4	4

#	ARTICLE	IF	CITATIONS
91	Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan. <i>Viruses</i> , 2021, 13, 2294.	1.5	4
92	Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. <i>American Journal of Cancer Research</i> , 2021, 11, 5526-5542.	1.4	0
93	Microbiota transplants from feces or gut content attenuated portal hypertension and portosystemic collaterals in cirrhotic rats. <i>Clinical Science</i> , 2021, 135, 2709-2728.	1.8	14
94	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. <i>Scientific Reports</i> , 2021, 11, 23473.	1.6	8
95	Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 218-229.	0.8	19
96	Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 125-133.	0.8	14
97	Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 610-620.	0.8	13
98	Outcomes of enteral metallic stent in patients with pancreatic carcinoma and gastric outlet obstruction: A single center experience. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 238-246.	0.8	7
99	Albumin-bilirubin grade-based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 205-214.	1.9	28
100	A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. <i>Digestive Diseases and Sciences</i> , 2020, 65, 658-667.	1.1	14
101	Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 18-24.	0.6	4
102	Risk of obstructive sleep apnea in patients with Sjögren syndrome and Behçet's disease: a nationwide, population-based cohort study. <i>Sleep and Breathing</i> , 2020, 24, 1199-1205.	0.9	10
103	Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 365-372.	0.8	2
104	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
105	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. <i>Cancers</i> , 2020, 12, 1862.	1.7	47
106	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020, 115, 1226-1235.	0.2	19
107	Cessation of nucleos(t)ide analogues for patients with chronic hepatitis B in Taiwan: Risky but inevitable. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 515-516.	0.6	0
108	A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. <i>Scientific Reports</i> , 2020, 10, 17259.	1.6	7

#	ARTICLE	IF	CITATIONS
109	Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure. <i>Scientific Reports</i> , 2020, 10, 18375.	1.6	14
110	Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. , 2020, 8, e001072.		45
111	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
112	The indocyanine green retention test as a noninvasive marker for esophageal varices in patients with hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 737-742.	0.6	2
113	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2719-2731.	1.9	32
114	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa397.	0.4	3
115	Post endoscopic retrograde cholangiopancreatography cholecystitis: The incidence and risk factors analysis. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 733-736.	0.6	5
116	Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2020, 120, 1676-1685.	0.8	3
117	Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 1071-1078.	0.6	1
118	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1019-1040.	0.8	60
119	Metavir Fibrosis Stage in Hepatitis C-Related Hepatocellular Carcinoma and Association with Noninvasive Liver Reserve Models. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1860-1862.	0.9	1
120	A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. <i>Liver Cancer</i> , 2020, 9, 245-260.	4.2	172
121	Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. <i>Cancers</i> , 2020, 12, 1130.	1.7	10
122	Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2096-2102.	1.4	1
123	Endoscopic papillary balloon dilatation less than three minutes for biliary stone removal increases the risk of post-ERCP pancreatitis. <i>PLoS ONE</i> , 2020, 15, e0233388.	1.1	5
124	Gastrointestinal and liver manifestations in patients with COVID-19. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 521-523.	0.6	165
125	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 2522-2534.	1.9	20
126	NAFLD Aggravates Septic Shock Due to Inadequate Adrenal Response and 11 β -HSDs Dysregulation in Rats. <i>Pharmaceutics</i> , 2020, 12, 403.	2.0	8

#	ARTICLE	IF	CITATIONS
127	Propranolol Suppresses the T-Helper Cell Depletion-Related Immune Dysfunction in Cirrhotic Mice. <i>Cells</i> , 2020, 9, 604.	1.8	12
128	Low but Long-lasting Risk of Reversal of Seroconversion in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2573-2581.e1.	2.4	20
129	Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 3925.	1.6	18
130	Large-scale genome-wide association study identifies HLA class II variants associated with chronic HBV infection: a study from Taiwan Biobank. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 682-691.	1.9	21
131	Antibiotic use in patients with acute cholecystitis after percutaneous cholecystostomy. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 134-140.	0.6	5
132	Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. <i>Scientific Reports</i> , 2020, 10, 2006.	1.6	7
133	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	1.7	74
134	Differential Survival Impact of Diabetes Mellitus on Hepatocellular Carcinoma: Role of Staging Determinants. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3389-3402.	1.1	2
135	Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes. <i>Liver International</i> , 2020, 40, 1089-1097.	1.9	14
136	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1135-1157.	0.8	69
137	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 5372.	1.6	4
138	Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 238-238.	0.7	17
139	Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF ₂ ±-activated COX-TXA2 pathway. <i>Clinical Science</i> , 2020, 134, 2055-2073.	1.8	9
140	Early echocardiographic signs of diastolic dysfunction predict acute kidney injury in cirrhotic patients. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 984-990.	0.6	6
141	Title is missing!. , 2020, 15, e0233388.		0
142	Title is missing!. , 2020, 15, e0233388.		0
143	Title is missing!. , 2020, 15, e0233388.		0
144	Title is missing!. , 2020, 15, e0233388.		0

#	ARTICLE	IF	CITATIONS
145	A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 1704-1712.	1.9	58
146	Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice. <i>BioMed Research International</i> , 2019, 2019, 1-14.	0.9	13
147	Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-8.	0.7	11
148	Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1014-1023.	0.8	9
149	The long term microbiota and metabolic status in patients with colorectal cancer after curative colon surgery. <i>PLoS ONE</i> , 2019, 14, e0218436.	1.1	15
150	Altered cognitive control network is related to psychometric and biochemical profiles in covert hepatic encephalopathy. <i>Scientific Reports</i> , 2019, 9, 6580.	1.6	8
151	Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 311-325.	2.0	16
152	An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE). <i>Infectious Diseases</i> , 2019, 220, 557-566.	1.9	15
153	Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease. <i>Laboratory Investigation</i> , 2019, 99, 1203-1216.	1.7	22
154	The role of regular liver function monitoring in antituberculosis drug-induced liver injury. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 535-540.	0.6	11
155	Predictors of stent occlusion in patients with unresectable pancreatic cancer after biliary metal stents. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 762-766.	0.6	4
156	A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 186-190.	0.6	3
157	Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 368-374.	0.6	14
158	Use of proton pump inhibitors and the risk of hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 756-761.	0.6	9
159	An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 698-704.	0.6	15
160	Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 693-698.	0.6	7
161	Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 2-10.	0.6	16
162	Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 595-598.	0.6	1

#	ARTICLE	IF	CITATIONS
163	To chew carefully and swallow slowly. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 745.	0.6	1
164	Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. <i>Hepatology</i> , 2019, 69, 1151-1164.	3.6	22
165	2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1385-1392.	0.8	19
166	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	0.8	11
167	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 7-38.	0.8	64
168	Elafibranor interrupts adipose dysfunction-mediated gut and liver injury in mice with alcoholic steatohepatitis. <i>Clinical Science</i> , 2019, 133, 531-544.	1.8	12
169	Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 776-781.	0.5	38
170	Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats. <i>Digestive Diseases and Sciences</i> , 2019, 64, 102-112.	1.1	26
171	Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 588-597.	0.8	18
172	Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. <i>Liver International</i> , 2018, 38, 1803-1811.	1.9	18
173	Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. <i>Scientific Reports</i> , 2018, 8, 843.	1.6	25
174	Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 289.	1.1	19
175	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. <i>Journal of Hepatology</i> , 2018, 69, 353-358.	1.8	270
176	Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. <i>Scientific Reports</i> , 2018, 8, 4773.	1.6	26
177	Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 321-330.	1.9	37
178	Esophageal varices are not predictive of patient prognosis after surgical resection of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1368-1377.	0.8	7
179	Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 15074.	1.6	8
180	Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1290-1300.	1.9	43

#	ARTICLE	IF	CITATIONS
181	Nucleos(t)ide Analogs Do Not Independently Influence Hepatic Fibrosis and Portal Hypertension beyond Viral Suppression in CBDL-Induced Cirrhotic Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 260-266.	1.3	1
182	Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus. <i>The American Journal of Chinese Medicine</i> , 2018, 46, 835-852.	1.5	21
183	Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α Agonist Aeglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension. <i>American Journal of Pathology</i> , 2018, 188, 1608-1624.	1.9	14
184	Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBsAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. <i>Journal of Infectious Diseases</i> , 2018, 218, 1075-1084.	1.9	16
185	The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. <i>Liver Cancer</i> , 2018, 7, 335-358.	4.2	27
186	Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1599-1607.	1.0	9
187	The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 111-118.	0.6	25
188	Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 412-412.	0.8	40
189	Improvement of non-alcoholic steatohepatitis by hepatocyte-like cells generated from iPSCs with Oct4/Sox2/Klf4/Parp1. <i>Oncotarget</i> , 2018, 9, 18594-18606.	0.8	13
190	Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients undergoing Biologics Treatment. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw606.	1.9	51
191	The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 42577.	1.6	25
192	Predictors of response to antiviral treatment for chronic hepatitis B. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 329-330.	0.6	0
193	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 389, 56-66.	6.3	2,771
194	Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. <i>Radiology</i> , 2017, 285, 670-680.	3.6	88
195	DNA Methyltransferases Modulate Hepatogenic Lineage Plasticity of Mesenchymal Stromal Cells. <i>Stem Cell Reports</i> , 2017, 9, 247-263.	2.3	14
196	Clinical efficacy of Rong-Yang-Jyh-Gan-Tang on patients with chronic hepatitis C: A double-blinded randomized placebo-controlled crossover study. <i>Journal of Ethnopharmacology</i> , 2017, 196, 1-8.	2.0	7
197	Is antibody to surface antigen associated with hepatitis B reactivation in patients with resolved hepatitis B?. <i>Hepatology</i> , 2017, 66, 1353-1353.	3.6	2
198	Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 125-132.	0.6	24

#	ARTICLE	IF	CITATIONS
199	The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. <i>European Radiology</i> , 2017, 27, 2600-2609.	2.3	13
200	ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 879-886.	1.4	126
201	Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. <i>Gastroenterology</i> , 2017, 152, 134-141.	0.6	133
202	Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections. <i>PLoS ONE</i> , 2017, 12, e0178841.	1.1	2
203	Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. <i>PLoS ONE</i> , 2017, 12, e0188552.	1.1	6
204	Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-12.	0.7	14
205	Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>PLoS ONE</i> , 2017, 12, e0180408.	1.1	31
206	Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. <i>PLoS ONE</i> , 2017, 12, e0188031.	1.1	14
207	Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients. <i>Medicine (United States)</i> , 2016, 95, e3064.	0.4	10
208	Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2 cm in a Propensity Score Model. <i>Annals of Surgery</i> , 2016, 263, 538-545.	2.1	148
209	Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice. <i>Scientific Reports</i> , 2016, 6, 18899.	1.6	18
210	Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. <i>Annals of Surgical Oncology</i> , 2016, 23, 874-883.	0.7	51
211	Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. <i>Scientific Reports</i> , 2016, 6, 29605.	1.6	37
212	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2016, 36, 1755-1764.	1.9	177
213	Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. <i>European Journal of Cancer</i> , 2016, 63, 25-33.	1.3	40
214	Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. <i>Journal of Hepatology</i> , 2016, 64, 601-608.	1.8	220
215	Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. <i>PLoS ONE</i> , 2016, 11, e0155588.	1.1	37
216	Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System. <i>Medicine (United States)</i> , 2015, 94, e1223.	0.4	11

#	ARTICLE	IF	CITATIONS
217	When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?. <i>Medicine (United States)</i> , 2015, 94, e1808.	0.4	26
218	Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2015, 94, e1341.	0.4	21
219	Interleukin-1 receptor antagonist correlates with hepatic venous pressure gradient and predicts occurrence of overall complications and bacterial infections in patients with cirrhosis. <i>Hepatology Research</i> , 2015, 45, 294-304.	1.8	3
220	Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 192-198.	1.4	4
221	Active Treatments Prolong the Survival in Patients With Hepatocellular Carcinoma and Performance Status 3 or 4. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 878-884.	1.1	3
222	External Validation of Fatty Liver Index for Identifying Ultrasonographic Fatty Liver in a Large-Scale Cross-Sectional Study in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0120443.	1.1	105
223	Detecting Minimal Hepatic Encephalopathy in an Endemic Country for Hepatitis B: The Role of Psychometrics and Serum IL-6. <i>PLoS ONE</i> , 2015, 10, e0128437.	1.1	20
224	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. <i>Annals of Hepatology</i> , 2015, 14, 181-189.	0.6	18
225	Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B. <i>Leukemia and Lymphoma</i> , 2015, 56, 2357-2364.	0.6	13
226	Prognosis of Early-Stage Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1929.	0.4	32
227	The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment. <i>Medicine (United States)</i> , 2015, 94, e1659.	0.4	8
228	Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice. <i>Medicine (United States)</i> , 2015, 94, e688.	0.4	30
229	Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1772.	0.4	21
230	Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients. <i>Medicine (United States)</i> , 2015, 94, e1321.	0.4	13
231	Aggressive Therapeutic Strategies Improve the Survival of Hepatocellular Carcinoma Patients with Performance Status 1 or 2: A Propensity Score Analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 1324-1331.	0.7	18
232	Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2015, 111, 404-409.	0.8	25
233	Radiofrequency Ablation is Better Than Surgical Resection in Patients With Hepatocellular Carcinoma Within the Milan Criteria and Preserved Liver Function. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 242-249.	1.1	33
234	Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease. <i>Journal of Hepatology</i> , 2015, 63, 1405-1412.	1.8	65

#	ARTICLE	IF	CITATIONS
235	Using Serum α -Fetoprotein for Prognostic Prediction in Patients with Hepatocellular Carcinoma: What is the Most Optimal Cutoff?. <i>PLoS ONE</i> , 2015, 10, e0118825.	1.1	36
236	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. <i>Annals of Hepatology</i> , 2015, 14, 181-9.	0.6	12
237	A New Child-Turcotte-Pugh Class 0 for Patients with Hepatocellular Carcinoma: Determinants, Prognostic Impact and Ability to Improve the Current Staging Systems. <i>PLoS ONE</i> , 2014, 9, e99115.	1.1	8
238	Uncompromised Treatment Efficacy in Elderly Patients With Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2014, 93, e264.	0.4	20
239	Vascular Invasion in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 734-741.	1.1	68
240	Regulation by resveratrol of the cellular factors mediating liver damage and regeneration after acute toxic liver injury. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 603-613.	1.4	31
241	Surgical Resection Versus Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. <i>Annals of Surgical Oncology</i> , 2014, 21, 1825-1833.	0.7	93
242	Benzodiazepine-Associated Hepatic Encephalopathy Significantly Increased Healthcare Utilization and Medical Costs of Chinese Cirrhotic Patients: 7-Year Experience. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1603-1616.	1.1	11
243	A Double-Blind Randomized Controlled Study to Evaluate the Efficacy of Low-Dose Oral Interferon-Alpha in Preventing Hepatitis C Relapse. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 187-194.	0.5	0
244	Long-term cannabinoid type 2 receptor agonist therapy decreases bacterial translocation in rats with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2014, 61, 1004-1013.	1.8	41
245	Survival Advantage of Radiofrequency Ablation Over Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Good Performance Status Within the Milan Criteria. <i>Annals of Surgical Oncology</i> , 2014, 21, 3835-3843.	0.7	19
246	Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1623-1631.	0.9	18
247	A Comparison of Clinical Manifestations and Prognoses Between Patients with Hepatocellular Carcinoma and Child-Pugh Scores of 5 or 6. <i>Medicine (United States)</i> , 2014, 93, e348.	0.4	17
248	Decrypting Cryptogenic Hepatocellular Carcinoma: Clinical Manifestations, Prognostic Factors and Long-Term Survival by Propensity Score Model. <i>PLoS ONE</i> , 2014, 9, e89373.	1.1	13
249	α -Fetoprotein-to-Total Tumor Volume Ratio Predicts Post-operative Tumor Recurrence in Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 730-738.	0.9	23
250	Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 645-654.	1.9	17
251	Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. <i>Hepatology International</i> , 2013, 7, 188-198.	1.9	36
252	The role of mTOR inhibitors in the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2013, 33, 1133-1134.	1.9	1

#	ARTICLE	IF	CITATIONS
253	Total Tumor Volume Is a Better Marker of Tumor Burden in Hepatocellular Carcinoma Defined by the Milan Criteria. <i>World Journal of Surgery</i> , 2013, 37, 1348-1355.	0.8	26
254	Validation of the behavior and concept based assessment of professionalism competence in postgraduate first-year residents. <i>Journal of the Chinese Medical Association</i> , 2013, 76, 186-194.	0.6	6
255	Performance Status Enhances the Selection of Treatment for Patients with Hepatocellular Carcinoma Within the Milan Criteria. <i>Annals of Surgical Oncology</i> , 2013, 20, 2035-2042.	0.7	17
256	Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B. <i>Journal of Clinical Oncology</i> , 2013, 31, 2765-2772.	0.8	292
257	Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. <i>Hepatology</i> , 2013, 57, 112-119.	3.6	168
258	Hepatocellular carcinoma in uremic patients: Is there evidence for an increased risk of mortality?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 348-356.	1.4	11
259	Reply to S. Kusumoto et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 4481-4481.	0.8	2
260	Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. <i>International Journal of Cancer</i> , 2013, 133, 2895-2902.	2.3	49
261	Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE. <i>PLoS ONE</i> , 2013, 8, e64365.	1.1	15
262	Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up. <i>PLoS ONE</i> , 2013, 8, e72049.	1.1	76
263	CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study. <i>PLoS ONE</i> , 2013, 8, e76798.	1.1	18
264	Aliskiren Attenuates Steatohepatitis and Increases Turnover of Hepatic Fat in Mice Fed with a Methionine and Choline Deficient Diet. <i>PLoS ONE</i> , 2013, 8, e77817.	1.1	23
265	Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. <i>Annals of Hepatology</i> , 2013, 12, 263-273.	0.6	18
266	IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e58071.	1.1	26
267	Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation. <i>Annals of Hepatology</i> , 2013, 12, 263-73.	0.6	7
268	Prognostic Significance of Computed Tomography Scan-derived Splenic Volume in Hepatocellular Carcinoma Treated With Radiofrequency Ablation. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 789-795.	1.1	19
269	Younger Hepatocellular Carcinoma Patients Have Better Prognosis After Percutaneous Radiofrequency Ablation Therapy. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 62-70.	1.1	56
270	Aliskiren attenuates chronic carbon tetrachloride-induced liver injury in mice. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1261-1271.	1.7	13

#	ARTICLE	IF	CITATIONS
271	Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1581-1588.	1.4	11
272	Comparison of Surgical Resection and Transarterial Chemoembolization for Hepatocellular Carcinoma beyond the Milan Criteria: A Propensity Score Analysis. <i>Annals of Surgical Oncology</i> , 2012, 19, 842-849.	0.7	108
273	Management of chemotherapy-induced hepatitis B virus reactivation. <i>Journal of the Chinese Medical Association</i> , 2012, 75, 359-362.	0.6	16
274	Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. <i>Digestive and Liver Disease</i> , 2012, 44, 868-874.	0.4	10
275	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. <i>Hepatology International</i> , 2012, 6, 753-762.	1.9	20
276	A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways. <i>Journal of Nutritional Biochemistry</i> , 2012, 23, 458-468.	1.9	114
277	Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: A propensity score analysis and staging strategy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 690-699.	1.4	12
278	Clinical significance of chronic hepatitis B virus infection in patients with primary Sjögren's syndrome. <i>Clinical Rheumatology</i> , 2012, 31, 309-315.	1.0	15
279	The Role of Interferon- β Inducible Protein-10 in a Mouse Model of Acute Liver Injury Post Induced Pluripotent Stem Cells Transplantation. <i>PLoS ONE</i> , 2012, 7, e50577.	1.1	11
280	Survival Rates Are Comparable After Radiofrequency Ablation or Surgery in Patients With Small Hepatocellular Carcinomas. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 79-86.	2.4	151
281	Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1.	0.8	53
282	Comparative Analysis of Noninvasive Models to Predict Early Liver Fibrosis in Hepatitis B e Antigen-negative Chronic Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 278-285.	1.1	28
283	Liver Failure After Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma and Ascites. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 556-562.	1.1	49
284	Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. <i>Clinical Nutrition</i> , 2011, 30, 647-652.	2.3	21
285	Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. <i>Hepatology International</i> , 2011, 5, 975-984.	1.9	13
286	Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: A propensity score analysis. <i>Liver Transplantation</i> , 2011, 17, 556-566.	1.3	63
287	The protective role of natural phytoalexin resveratrol on inflammation, fibrosis and regeneration in cholestatic liver injury. <i>Molecular Nutrition and Food Research</i> , 2011, 55, 1841-1849.	1.5	63
288	Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Renal Insufficiency. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e171-e177.	1.1	29

#	ARTICLE	IF	CITATIONS
289	Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. <i>Hepatology International</i> , 2010, 4, 691-699.	1.9	60
290	Selecting an optimal staging system for hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 3006-3014.	2.0	88
291	Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. <i>Liver International</i> , 2010, 30, 77-84.	1.9	34
292	Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. <i>Liver International</i> , 2010, 30, 198-207.	1.9	30
293	Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of Î±-fetoprotein. <i>Liver International</i> , 2010, 30, 1161-1168.	1.9	10
294	Core Antigen Expression Is Associated with Hepatic Necroinflammation in e Antigen-Negative Chronic Hepatitis B Patients with Low DNA Loads. <i>Vaccine Journal</i> , 2010, 17, 1048-1053.	3.2	7
295	A new prognostic model for hepatocellular carcinoma based on total tumor volume: The Taipei Integrated Scoring system. <i>Journal of Hepatology</i> , 2010, 53, 108-117.	1.8	157
296	Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma. <i>Journal of the Chinese Medical Association</i> , 2010, 73, 156-160.	0.6	27
297	Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection?. <i>Liver International</i> , 2009, 29, 767-773.	1.9	19
298	Generation of cytotoxicity against hepatitis delta virus genotypes and quasispecies by epitope modification. <i>Journal of Hepatology</i> , 2009, 50, 779-788.	1.8	4
299	Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2009, 51, 890-897.	1.8	369
300	2009 Novel H1N1 Influenza: The Impact of Viral Genomic Reassortment on Immune Evasion and Vaccine Strategy. <i>Journal of the Chinese Medical Association</i> , 2009, 72, 281-282.	0.6	4
301	Selecting a Short-term Prognostic Model for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 773-781.	1.1	21
302	Fatal Reactivation of Hepatitis B Virus in a Patient Who Was Hepatitis B Surface Antigen Negative and Core Antibody Positive Before Receiving Chemotherapy for Non-Hodgkin Lymphoma. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 496-498.	1.1	24
303	Predictive Value of Aspartate Aminotransferase to Alanine Aminotransferase Ratio for Hepatic Fibrosis and Clinical Adverse Outcomes in Patients With Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 876-883.	1.1	25
304	Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. <i>Liver International</i> , 2008, 28, 1305-1313.	1.9	23
305	Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. <i>Clinical Transplantation</i> , 2008, 22, 469-475.	0.8	34
306	Successful Radiofrequency Ablation Therapy for Hepatocellular Carcinoma in a Male Patient with Early Stage Primary Biliary Cirrhosis and Positive Serum Hepatitis B Core Antibody. <i>Journal of the Chinese Medical Association</i> , 2008, 71, 40-44.	0.6	1

#	ARTICLE	IF	CITATIONS
307	Cholestatic Jaundice as the Predominant Presentation in a Patient with Autoimmune Hepatitis. <i>Journal of the Chinese Medical Association</i> , 2008, 71, 45-48.	0.6	4
308	Hepatitis B Surface Antigen Levels and Sequences of Natural Hepatitis B Virus Variants Influence the Assembly and Secretion of Hepatitis D Virus. <i>Journal of Virology</i> , 2008, 82, 2250-2264.	1.5	55
309	Positive Selection of Hepatitis Delta Antigen in Chronic Hepatitis D Patients. <i>Journal of Virology</i> , 2007, 81, 4438-4444.	1.5	20
310	Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: Is there a lead-time bias?. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 485-492.	0.6	27
311	Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. <i>Journal of Hepatology</i> , 2007, 47, 128-134.	1.8	191
312	The predictive ability of serum α -fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance. <i>Journal of Surgical Oncology</i> , 2007, 95, 645-651.	0.8	11
313	Analysis of Humoral Immunity of Hepatitis D Virus DNA Vaccine Generated in Mice by Using Different Dosage, Gene Gun Immunization, and In Vivo Electroporation. <i>Journal of the Chinese Medical Association</i> , 2006, 69, 7-13.	0.6	11
314	Genotypes and Viremia of Hepatitis B and D Viruses Are Associated With Outcomes of Chronic Hepatitis D Patients. <i>Gastroenterology</i> , 2006, 130, 1625-1635.	0.6	193
315	The Sequential Changes of the Model for End-stage Liver Disease Score Correlate With the Severity of Liver Cirrhosis in Patients With Hepatocellular Carcinoma Undergoing Locoregional Therapy. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 543-550.	1.1	17
316	Fever and Infectious Complications After Percutaneous Acetic Acid Injection Therapy for Hepatocellular Carcinoma: Incidence and Risk Factor Analysis. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 639-642.	1.1	7
317	The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. <i>Cancer</i> , 2006, 107, 141-148.	2.0	54
318	Proposal of a Modified Cancer of the Liver Italian Program Staging System Based on the Model for End-Stage Liver Disease for Patients with Hepatocellular Carcinoma Undergoing Loco-Regional Therapy. <i>American Journal of Gastroenterology</i> , 2006, 101, 975-982.	0.2	47
319	Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. <i>Liver International</i> , 2005, 25, 236-241.	1.9	63
320	Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 765-771.	1.4	53
321	Staging for hepatocellular carcinoma: Treatment strategy matters. <i>Hepatology</i> , 2005, 41, 678-678.	3.6	8
322	Percutaneous Ablation Therapy for Hepatocellular Carcinoma: Current Practice and Future Perspectives. <i>Journal of the Chinese Medical Association</i> , 2005, 68, 155-159.	0.6	35
323	Identification of novel HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. <i>Journal of General Virology</i> , 2004, 85, 3089-3098.	1.3	57
324	Differential Mechanism and Prognostic Impact of Diabetes Mellitus on Patients with Hepatocellular Carcinoma Undergoing Surgical and Nonsurgical Treatment. <i>American Journal of Gastroenterology</i> , 2004, 99, 1479-1487.	0.2	58

#	ARTICLE	IF	CITATIONS
325	The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. <i>Liver International</i> , 2004, 24, 419-424.	1.9	25
326	Deterioration of Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma after Resection: Incidence, Risk Factors, and Association with Intrahepatic Tumor Recurrence. <i>World Journal of Surgery</i> , 2004, 28, 258-262.	0.8	28
327	Hepatitis C Virus Infection is a Risk Factor for Tumor Recurrence after Resection of Small Hepatocellular Carcinomas. <i>World Journal of Surgery</i> , 2004, 28, 787-791.	0.8	19
328	Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. <i>Liver Transplantation</i> , 2004, 10, 1507-1513.	1.3	21
329	Changing seroepidemiology of hepatitis B, C, and D virus infections in high-risk populations. <i>Journal of Medical Virology</i> , 2004, 72, 41-45.	2.5	29
330	Percutaneous injection therapy for hepatocellular carcinoma in patients with chronic renal insufficiency. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 325-331.	0.8	6
331	Selective prognostic impact of serum α -fetoprotein level in patients with hepatocellular carcinoma: Analysis of 543 patients in a single center. <i>Oncology Reports</i> , 2004, 11, 543.	1.2	7
332	Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. <i>Oncology Reports</i> , 2004, 11, 543-50.	1.2	19
333	Diabetes Mellitus Is A Risk Factor for Hepatic Decompensation in Patients With Hepatocellular Carcinoma Undergoing Resection: A Longitudinal Study. <i>American Journal of Gastroenterology</i> , 2003, 98, 2293-2298.	0.2	63
334	Varied Immunity Generated in Mice by DNA Vaccines with Large and Small Hepatitis Delta Antigens. <i>Journal of Virology</i> , 2003, 77, 12980-12985.	1.5	23
335	Polymorphism of The N -Acetyltransferase 2 Gene, Red Meat Intake, and The Susceptibility of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2003, 98, 1417-1422.	0.2	36
336	Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 1203-1208.	0.8	30
337	Survival Benefit of Cirrhotic Patients with Hepatocellular Carcinoma Treated by Percutaneous Ethanol Injection as a Salvage Therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 350-355.	0.6	29
338	Comparison of clinical manifestations and epidemiology between acute hepatitis A and acute hepatitis E in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 1187-1191.	1.4	13
339	Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: A report of two cases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 481-483.	1.4	12
340	Hereditary hemorrhagic telangiectasia: Demonstration of portosystemic venous shunts using power Doppler sonography and sonographically guided percutaneous transhepatic portovenography. <i>Journal of Clinical Ultrasound</i> , 2001, 29, 517-522.	0.4	6
341	Clinical and epidemiological implications of swine hepatitis E virus infection. <i>Journal of Medical Virology</i> , 2000, 60, 166-171.	2.5	83
342	Prevalence and risk factor analysis of TTV infection in prostitutes. , 2000, 60, 393-395.		11

#	ARTICLE	IF	CITATIONS
343	DNA-based immunization produces Th1 immune responses to hepatitis delta virus in a mouse model. <i>Hepatology</i> , 2000, 32, 104-110.	3.6	33
344	Diagnostic Value of Immunoglobulin G (IgG) and IgM Anti-Hepatitis E Virus (HEV) Tests Based on HEV RNA in an Area Where Hepatitis E Is Not Endemic. <i>Journal of Clinical Microbiology</i> , 2000, 38, 3915-3918.	1.8	70
345	Prospective Case-controlled Trial of Adjuvant Chemotherapy after Resection of Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2000, 24, 551-555.	0.8	39
346	Mixed genotypes infection with hepatitis D virus. <i>Journal of Medical Virology</i> , 1999, 57, 64-67.	2.5	34
347	Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 315-322.	0.8	46
348	Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited: A study of total and IgM anti-HDV compared with detection of HDV RNA by polymerase chain reaction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 57-61.	1.4	19
349	Prevalence, implication, and viral nucleotide sequence analysis of GB virus-C/hepatitis G virus infection in acute fulminant and nonfulminant hepatitis. , 1998, 56, 118-122.		12
350	Detection of serum hepatitis B, C, and D viral nucleic acids and its implications in hepatocellular carcinoma patients. <i>Journal of Gastroenterology</i> , 1998, 33, 512-516.	2.3	18
351	Prevalence and risk factor analysis of GBV-C/HGV infection in prostitutes. <i>Journal of Medical Virology</i> , 1997, 52, 83-85.	2.5	38
352	Prevalence and risk factor analysis of GBV-C/HGV infection in prostitutes. , 1997, 52, 83.		3
353	Right inguinal metastasis from hepatocellular carcinoma. <i>Advances in Digestive Medicine</i> , 0, , .	0.1	1
354	Efficacy and predictors of survival in patients with solitary hepatocellular carcinoma larger than 5 cm undergoing transarterial chemoembolization. <i>Advances in Digestive Medicine</i> , 0, , .	0.1	2